StockNews.AISignal intelligence
Company intelligence

KPTI

Karyopharm Therapeutics Inc. · NASDAQ · Healthcare

Price$0.02+5.88% · +$0.00
Market cap408.27KEquity value
P / E0.0Trailing ratio
Volume8.28MLatest session
Market data

KPTI price chart

TradingView
Related signals
1 min delayed

Browse public KPTI signals with their source context and measured market impact. Open any signal for its permanent analysis page.

KPTIMar 24, 2026-21.39% since signal

Karyopharm's SENTRY Trial Shows Promising Results for Myelofibrosis Treatment

Karyopharm Therapeutics reported positive topline results from its Phase 3 SENTRY trial, achieving the primary endpoint of spleen volume reduction in myelofibrosis patients. The trial also hints at improved overall survival, leading Karyopharm to plan an FDA meeting for a potential supplemental new drug application filing, which could enhance marketability and investor confidence.

View signal analysis
Research

Company intelligence